dipyridamole has been researched along with Hemorrhagic Disease of Newborn in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Hemorrhagic Disease of Newborn: Neonatal nasogastric or intracranial hemorrhage caused by vitamin K deficiency.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Gaetano, G | 1 |
| Donati, MB | 1 |
| Garattini, S | 1 |
1 other study available for dipyridamole and Hemorrhagic Disease of Newborn
| Article | Year |
|---|---|
Drugs affecting platelet function tests: their effects on haemostasis and surgical bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Disorders; Blood Donors; Blood P | 1975 |